Xiangmin Lv

Xiangmin (Sherman) LV is a Senior Scientist at Moderna, focusing on mRNA cancer vaccine development since July 2023. Prior experience includes roles as Scientist II and Scientist I at Agenus, specializing in immune-oncology and vaccine immunology from September 2021 to June 2023. LV's research background encompasses postdoctoral fellowships at Massachusetts General Hospital and Harvard Medical School, where investigations centered on Hippo signaling's impact on the tumor immune microenvironment and angiogenesis. Earlier academic work at the University of Nebraska Medical Center involved establishing models for ovarian and cervical cancer and exploring the therapeutic potential of the G-1 compound. LV holds a Ph.D. in Biomedical Sciences and an M.S. in Cell Biology from the University of Nebraska Medical Center, complemented by a postdoctoral fellowship in immuno-oncology and cancer biology at Harvard Medical School.